BASKING RIDGE, NJ, May 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the first quarter ended March 31, 2021.
John Koconis, Chairman and Chief Executive Officer of Timber, commented, “In the first quarter Timber continued to advance on all of its programs.
We look forward to holding our first shareholder meeting as a public company on June 3rd, 2021 for shareholders of record as of April 12, 2021,” concluded Mr. Koconis.
For Timber’s complete financial results for the period ended March 31, 2021, see the Company’s quarterly Form 10-Q filed with the Securities and Exchange Commission on May 11, 2021.
About Timber Pharmaceuticals, Inc.Timber Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases. The Company's investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing and control) and safety profiles. The Company is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), facial angiofibromas (FAs) in tuberous sclerosis complex (TSC), and scleroderma. For more information, visit www.timberpharma.com .
Forward-Looking StatementsThis press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, intellectual property rights, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
For more information, contact: Timber Pharmaceuticals, Inc. John Koconis Chairman and Chief Executive Officer jkoconis@timberpharma.com Investor Relations: Stephanie Prince PCG Advisory (646) 863-6341 sprince@pcgadvisory.com Media Relations: Adam Daley Berry & Company Public Relations (212) 253-8881 adaley@berrypr.com Jenna Urban Berry & Company Public Relations (212) 253-8881 jurban@berrypr.com- Tables Follow -
Timber Pharmaceuticals, Inc. & Subsidiaries Condensed Consolidated Balance Sheets
March 31, | December 31, | ||
2021 | 2020 | ||
ASSETS | (unaudited) | ||
Current assets | |||
Cash | $ 8,500,053 | $ 10,348,693 | |
Other current assets | 291,929 | 377,290 | |
Total current assets | 8,791,982 | 10,725,983 | |
Deposits | 127,534 | 114,534 | |
Right of use asset | 854,184 | 787,432 | |
Total assets | $ 9,773,700 | $ 11,627,949 | |
LIABILITIES AND MEMBERS' AND STOCKHOLDERS' EQUITY | |||
Current liabilities | |||
Accounts payable | $ 523,793 | $ 395,049 | |
Accrued expenses | 532,373 | 768,661 | |
Lease liability, current portion | 278,059 | 217,651 | |
Total current liabilities | 1,334,225 | 1,381,361 | |
Notes payable | 37,772 | 37,772 | |
Lease liability | 588,087 | 579,455 | |
Deferred tax liability | 37,842 | 37,842 | |
Other liabilities | 73,683 | 73,683 | |
Total liabilities | 2,071,609 | 2,110,113 | |
Commitments and contingencies (Note 8) | |||
Redeemable Series A convertible preferred stock, par value $0.001; 2,500 shares authorized; 1,819 shares issued and outstanding as of March 31, 2021 and December 31, 2020 | 1,945,692 | 1,909,805 | |
Stockholders' equity | |||
Common stock, par value $0.001; 450,000,000 shares authorized; 36,659,685 shares issued and outstanding as of March 31, 2021, and 27,132,420 shares issued and outstanding as of December 31, 2020 | 36,660 | 27,132 | |
Additional paid-in capital | 25,839,395 | 25,826,295 | |
Accumulated deficit | (20,119,656) | (18,245,396) | |
Total stockholders' equity | 5,756,399 | 7,608,031 | |
Total liabilities, redeemable convertible preferred stock, and stockholders' equity | $ 9,773,700 | $ 11,627,949 |
Timber Pharmaceuticals, Inc. & Subsidiaries Condensed Consolidated Statements of Operations (Unaudited)
Three months ended March 31, | |||
2021 | 2020 | ||
Grant revenues | $ 40,734 | $ 26,907 | |
Operating costs and expenses | |||
Research and development | 849,518 | 1,018,231 | |
Transaction costs | - | 1,189,842 | |
Selling, general and administrative | 1,065,389 | 456,794 | |
Total operating expenses | 1,914,907 | 2,664,867 | |
Loss from operations | (1,874,173) | (2,637,960) | |
Other income (expense) | |||
Interest expense | - | (1,102,606) | |
Interest income | - | 456,775 | |
Change in fair value of investment in BioPharmX | - | 83,560 | |
Change in fair value of warrant liability | - | (321,051) | |
(Loss) gain on foreign currency exchange | (87) | 2,682 | |
Total other expense | (87) | (880,640) | |
Net loss | (1,874,260) | (3,518,600) | |
Accrued dividend on preferred stock units | - | (34,481) | |
Cumulative dividends on Series A preferred stock | (35,887) | - | |
Net loss attributable to common stockholders | $ (1,910,147) | $ (3,553,081) | |
Basic and diluted net loss per share attributable to common stockholders | $ (0.05) | $ (0.56) | |
Basic and diluted weighted average number of shares outstanding | 35,079,143 | 6,295,724 |